8-K: Lineage Cell Therapeutics Reports Durable 36-Month Visual Acuity Gains for OpRegen in Geographic Atrophy

Lineage Cell Therapeutics announced positive 36-month visual acuity and retinal structural improvement results from its Phase 1/2a clinical study of OpRegen (RG6501) for geographic atrophy secondary to age-related macular degeneration.

Summary

• Lineage Cell Therapeutics, Inc. (Lineage) issued a press release announcing 36-month visual acuity results from patients enrolled in a Phase 1/2a clinical study of RG6501 (OpRegen) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
• The results were presented at Clinical Trials at the Summit (CTS) 2025 on June 20, 2025.
• Improvement in visual acuity in Cohort 4 patients (those with less advanced GA) was present at 12 months (primary endpoint), 24 months, and persisted through 36 months.
• The mean change in Best Corrected Visual Acuity (BCVA) among treated eyes for 10 patients completing 3-year follow-up was +6.2 letters, an increase from +5.5 letters at 24 months (Early Treatment Diabetic Retinopathy Study (ETDRS) assessment).
• For the five patients with extensive OpRegen bleb coverage of their GA area, the mean change in BCVA was even greater, reaching +9.0 ETDRS letters at 36 months, up from +7.4 ETDRS letters at 24 months.
• Sustained evidence of retinal structural improvement, as observed by quantitative Optical Coherence Tomography (OCT) analysis, was noted through 36 months in treated eyes of Cohort 4 patients.
• Specifically, mean improvement of RPEDC (RPE drusen complex) area compared with baseline was maintained in treated eyes from 24 months (+2.6 mm2; n=4) to 36 months (+1.9 mm2; n=5), while decreasing in untreated fellow eyes (-2.8 mm2 to -3.8 mm2).
• Mean change in ELM (external limiting membrane) area was maintained in treated eyes from 24 months (+0.8 mm2; n=4) to 36 months (+0.3 mm2; n=5), contrasting with decreases in untreated fellow eyes (-1.9 mm2 to -3.4 mm2).
• These data suggest that OpRegen cell therapy may counteract RPE cell dysfunction and loss in GA by supporting remaining retinal cells, with effects appearing durable for at least 36 months after a single administration.
• RG6501 (OpRegen) is being developed under an exclusive worldwide collaboration between Lineage, Roche, and Genentech.
• A Phase 2a clinical study, known as the GAlette study (NCT05626114), is currently enrolling patients to evaluate the success of subretinal delivery of OpRegen cell therapy and test proprietary surgical devices.

Sentiment

Score: 9

Explanation: The document reports highly positive and durable clinical trial results for OpRegen in treating geographic atrophy, a significant unmet medical need. The sustained visual and structural improvements over 36 months from a single administration are very promising and challenge existing views on the irreversibility of GA. The strong collaboration with Roche and Genentech adds significant credibility and resources to the program. While standard clinical trial risks are present, the overall data presented is exceptionally strong.

Positives

• Visual acuity improvement in Cohort 4 patients persisted through 36 months following a single administration of OpRegen cell therapy.
• Mean change in Best Corrected Visual Acuity (BCVA) for all 10 patients completing 3-year follow-up was +6.2 letters, an increase from +5.5 letters at 24 months.
• Patients with extensive OpRegen cell therapy coverage (n=5) showed even greater mean BCVA gains of +9.0 ETDRS letters at 36 months, up from +7.4 letters at 24 months.
• Sustained evidence of retinal structural improvement by quantitative OCT analysis was observed through 36 months in treated eyes.
• Specific improvements in external limiting membrane (ELM) and RPE drusen complex (RPEDC) layers were maintained in treated eyes, contrasting with decreases in untreated fellow eyes.
• The data suggest OpRegen cell therapy may counteract RPE cell dysfunction and loss in GA, providing support to remaining retinal cells.
• The effects of OpRegen appear durable through at least 36 months after a single administration, challenging the long-held view that GA causes irreversible damage.
• OpRegen is being developed under an exclusive worldwide collaboration with Roche and Genentech, indicating strong partnership and resources.

Risks

• Positive findings in early clinical studies of a product candidate may not be predictive of success in subsequent clinical studies of that candidate.
• Roche and Genentech may not successfully advance OpRegen or be successful in completing clinical trials for OpRegen and/or obtaining regulatory approval for OpRegen in any particular jurisdiction.
• The ongoing Israeli regional conflict may materially and adversely impact Lineage's manufacturing processes, including cell banking and product manufacturing for cell therapy product candidates, which are conducted by its subsidiary in Jerusalem, Israel.
• Lineage may not be able to manufacture sufficient clinical quantities of its product candidates in accordance with current good manufacturing practice.
• Other risks and uncertainties inherent in Lineage's business and discussed in its periodic reports with the SEC, including its most recent Annual Report on Form 10-K.

Future Outlook

The data suggest that OpRegen cell therapy has the potential to counteract RPE cell dysfunction and loss in GA by supporting remaining retinal cells, with durable effects through at least 36 months. The ongoing Phase 2a GAlette study is actively enrolling patients to further evaluate subretinal delivery success and test proprietary surgical devices designed to improve delivery, with partners Roche and Genentech continuing to advance the program.

Management Comments

• "Long term clinical outcomes following a single administration of OpRegen cell therapy is challenging the long-held view that GA causes irreversible damage." Brian M. Culley, Lineage CEO.
• "A key finding from the Lineage-run phase 1/2a trial was the importance of extensive placement of cells across the area of atrophy." Brian M. Culley, Lineage CEO.
• "Among patients who received fulsome coverage by OpRegen cell therapy, anatomical and functional benefits from a single administration have lasted for at least three years." Brian M. Culley, Lineage CEO.
• "Over this extended period, improved visual function is not a natural occurrence among patients suffering from GA, making these changes quite promising." Brian M. Culley, Lineage CEO.
• "Importantly, OpRegen-treated eyes have exhibited mean BCVA scores above baseline at each of the 12-, 24-, and 36-month timepoints, demonstrating consistency as well as durability." Brian M. Culley, Lineage CEO.
• "In short, patients who received significant coverage of OpRegen cell therapy across their GA are exhibiting long-term outcomes consistent with meaningful disease stabilization and even improvement." Brian M. Culley, Lineage CEO.
• "We are excited to see any additional insights which our partners, Roche and Genentech, may uncover from the ongoing GAlette study, which is investigating the best way to deliver OpRegen cell therapy to patients with GA secondary to age related macular degeneration (AMD)." Brian M. Culley, Lineage CEO.

Industry Context

Geographic Atrophy (GA) is an advanced form of age-related macular degeneration (AMD) and a leading cause of adult blindness globally, affecting at least 5 million people. It is characterized by severe loss of visual function, and historically, GA has been considered to cause irreversible damage. The positive and durable long-term visual and structural improvements demonstrated by OpRegen, particularly after a single administration, represent a significant potential breakthrough in a disease with high unmet medical need. The ongoing collaboration with pharmaceutical giants Roche and Genentech further underscores the potential importance of this therapy within the ophthalmology and regenerative medicine sectors.

Comparison to Industry Standards

• The document highlights that "improved visual function is not a natural occurrence among patients suffering from GA," implying that OpRegen's observed gains are significantly better than the typical progression of the disease.
• Management states that the long-term outcomes are "challenging the long-held view that GA causes irreversible damage," suggesting a potential paradigm shift in the treatment of this condition compared to historical understanding and outcomes.
• While specific comparable companies or projects are not named, the sustained anatomical and functional benefits from a single administration for at least three years are presented as highly promising in the context of a degenerative eye disease.

Stakeholder Impact

• Shareholders: The highly positive and durable clinical data for OpRegen could significantly increase investor confidence and potentially lead to a positive impact on the company's share price.
• Patients: Individuals suffering from geographic atrophy secondary to AMD could benefit from a potentially effective and long-lasting treatment option for a condition that currently has limited therapeutic solutions and is considered to cause irreversible damage.
• Employees: Positive clinical trial outcomes validate the company's research and development efforts, potentially boosting morale and attracting talent.
• Partners (Roche and Genentech): The strong results reinforce the value of their exclusive worldwide collaboration with Lineage, potentially leading to further investment and advancement of the OpRegen program.

Next Steps

• The Phase 2a GAlette study (NCT05626114) is currently enrolling patients to evaluate the success of subretinal delivery of OpRegen cell therapy to target areas of GA.
• The GAlette study will test proprietary surgical devices in development for subretinal delivery of OpRegen cell therapy that have potential advantages over currently available devices and procedures.
• Roche and Genentech are expected to uncover additional insights from the ongoing GAlette study.

Key Dates

Recommendation

Keywords

Lineage Cell Therapeutics, OpRegen, RG6501, Geographic Atrophy, GA, Age-related Macular Degeneration, AMD, Retinal Pigment Epithelium, RPE, Cell Therapy, Clinical Trial, Phase 1/2a, Phase 2a, GAlette, Visual Acuity, BCVA, OCT, Ophthalmology, Biotechnology, Regenerative Medicine, Roche, Genentech, LCTX